Literature DB >> 29071542

Infant with hepatomegaly and hypoglycemia: A setting for fatty acid oxidation defects.

Aathira Ravindranath1, Gautham Pai1, Anshu Srivastava2, Ujjal Poddar1, Surender Kumar Yachha1.   

Abstract

Fatty acid oxidation defects (FAOD) are one of the commonest metabolic liver diseases (MLDs) that can have varied presentations in different age groups. An infant presented with short history of jaundice and irritability, examination showed soft hepatomegaly. Investigations revealed non-ketotic hypoglycemia suggesting FAOD which was later confirmed as carnitine uptake defect with gas chromatography and mass spectrometry and mutation analysis. Patient improved with acute management of metabolic crisis, carnitine supplementation and corn starch therapy with reversal of encephalopathy, reduction in hepatomegaly, maintenance of euglycemia and improvement in liver function tests and creatine phosphokinase on follow up. Non-ketotic hypoglycemia is a characteristic finding in FAODs. Early diagnosis and appropriate management can result in excellent outcomes in patients with FAODs.

Entities:  

Keywords:  Fatty acid oxidation defects; Hepatomegaly; Hypoglycemia; Metabolic liver disease; Primary carnitine deficiency

Mesh:

Substances:

Year:  2017        PMID: 29071542     DOI: 10.1007/s12664-017-0790-0

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  11 in total

1.  Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop.

Authors:  U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel
Journal:  J Inherit Metab Dis       Date:  2009-04-28       Impact factor: 4.982

2.  Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients.

Authors:  Julien Baruteau; Philippe Sachs; Pierre Broué; Michèle Brivet; Hendy Abdoul; Christine Vianey-Saban; Hélène Ogier de Baulny
Journal:  J Inherit Metab Dis       Date:  2012-10-03       Impact factor: 4.982

3.  The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005.

Authors:  D M Frazier; D S Millington; S E McCandless; D D Koeberl; S D Weavil; S H Chaing; J Muenzer
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

4.  The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results.

Authors:  Ronald J A Wanders; Jos P N Ruiter; Lodewijk IJLst; Hans R Waterham; Sander M Houten
Journal:  J Inherit Metab Dis       Date:  2010-05-20       Impact factor: 4.982

Review 5.  Pathophysiology of fatty acid oxidation disorders.

Authors:  M J Bennett
Journal:  J Inherit Metab Dis       Date:  2009-10-10       Impact factor: 4.982

Review 6.  Disorders of carnitine biosynthesis and transport.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2015-09-10       Impact factor: 4.797

Review 7.  Genetic disorders of carnitine metabolism and their nutritional management.

Authors:  J Kerner; C Hoppel
Journal:  Annu Rev Nutr       Date:  1998       Impact factor: 11.848

Review 8.  Mitochondrial fatty-acid oxidation disorders.

Authors:  Michelle Kompare; William B Rizzo
Journal:  Semin Pediatr Neurol       Date:  2008-09       Impact factor: 1.636

Review 9.  Clinical and biochemical monitoring of patients with fatty acid oxidation disorders.

Authors:  Allan Meldgaard Lund; Flemming Skovby; Helle Vestergaard; Mette Christensen; Ernst Christensen
Journal:  J Inherit Metab Dis       Date:  2010-01-12       Impact factor: 4.982

Review 10.  Fatty acid oxidation disorders: outcome and long-term prognosis.

Authors:  Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2010-01-05       Impact factor: 4.982

View more
  1 in total

Review 1.  The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Dragana Savic; Leanne Hodson; Stefan Neubauer; Michael Pavlides
Journal:  Nutrients       Date:  2020-07-22       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.